| impact of hepatitis c seropositivity on the risk of coronary heart disease events. | chronic infections have been shown to enhance atherogenicity. however, the association between chronic hepatitis c (hcv) and coronary heart disease (chd) remains controversial. we examined the risk for chd events in patients with hcv with an emphasis on the risk of chd events with active infection. we conducted a retrospective cohort study using the enterprise data warehouse at the university of arkansas for medical sciences. hcv positive and negative patients were identified based on serology, ... | 2014 | 25438910 |
| hepatitis c in arkansas: updates on epidemiology, testing and treatment. | hepatitis c infection is the most common blood-borne infection in the united states with an estimated 2.7 million individuals suffering from chronic infection. of those who are infected with hepatitis c virus, 75-85% develop chronic infection. without treatment for chronic infection, individuals can develop liver diseases, such as cirrhosis and hepatocellular carcinoma, during many years of asymptomatic infection. to examine the burden of hepatitis c virus infection in the state, the arkansas de ... | 2015 | 25966598 |
| comparison of angiographic burden of coronary artery disease in patients with versus without hepatitis c infection. | hepatitis c virus (hcv) infection is thought to be associated with an increased risk of coronary heart disease (chd) events, perhaps secondary to increased inflammation. we sought to examine the angiographic burden of coronary artery disease (cad) in patients with hcv compared to hcv-negative patients. all consecutive hcv rna-positive patients (n = 61) who underwent coronary angiography at the university of arkansas for medical sciences from 2001 to 2013 were identified. a parallel group of hcv- ... | 2015 | 26256578 |
| canadians seek justice probe in sale of prison blood. | a group of canadians requested that the u.s. department of justice investigate the sale of blood donated from arkansas prisoners to canada in the 1980s. the u.s. food and drug administration ruled the blood was unfit for use in the united states in 1983. the group has brought a $1.1 billion suit against canadian officials, claiming they allowed the purchase of hiv-positive and hepatitis c-infected blood. a similar suit is expected to be brought against u.s. authorities and there are plans to sub ... | 1999 | 11367343 |